Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island, USA.
Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Paediatr Perinat Epidemiol. 2022 Jul;36(4):536-547. doi: 10.1111/ppe.12825. Epub 2021 Dec 3.
Maternal HIV and antiretroviral therapy (ART) exposure in utero may influence infant weight, but the contribution of maternal y body mass index (BMI) to early life overweight and obesity is not clear.
To estimate associations between maternal BMI at entry to antenatal care (ANC) and infant weight through approximately 1 year of age and to evaluate whether associations were modified by maternal HIV status, maternal HIV and viral load, breastfeeding intensity through 6 months or timing of entry into ANC.
We followed HIV-uninfected and -infected pregnant women initiating efavirenz-based ART from first antenatal visit through 12 months postpartum. Infant weight was assessed via World Health Organization BMI and weight-for-length z-scores (WLZ) at 6 weeks, 3, 6, 9 and 12 months. We used multivariable linear mixed-effects models to estimate associations between maternal BMI and infant z-scores over time.
In 861 HIV-uninfected infants (454 HIV-exposed; 407 HIV-unexposed), nearly 20% of infants were overweight or obese by 12 months of age, regardless of HIV exposure status. In multivariable analyses, increasing maternal BMI category was positively associated with higher infant BMIZ and WLZ scores between 6 weeks and 12 months of age and did not differ by HIV exposure status. However, HIV-exposed infants had slightly lower BMIZ and WLZ trajectories through 12 months of age, compared with HIV-unexposed infants across all maternal BMI categories. Differences in BMIZ and WLZ scores by HIV exposure were not explained by timing of entry into ANC or maternal viral load pre-ART initiation, but z-scores were slightly higher for HIV-exposed infants who were predominantly or exclusively versus partially breastfed.
These findings suggest maternal BMI influences early infant weight gain, regardless of infant HIV exposure status. Intervention to reduce maternal BMI may help to address growing concerns about obesity among HIV-uninfected children.
母体艾滋病毒和抗逆转录病毒治疗(ART)在子宫内的暴露可能会影响婴儿的体重,但母体体重指数(BMI)对婴儿超重和肥胖的早期影响尚不清楚。
通过大约 1 年的时间,估计母体进入产前保健(ANC)时的 BMI 与婴儿体重之间的关联,并评估这些关联是否因母体 HIV 状况、母体 HIV 和病毒载量、6 个月时的母乳喂养强度或 ANC 进入时间而改变。
我们跟踪了首次产前就诊时开始接受基于依非韦伦的 ART 的未感染 HIV 和感染 HIV 的孕妇,直至产后 12 个月。婴儿体重通过世界卫生组织 BMI 和体重-身长 Z 分数(WLZ)在 6 周、3、6、9 和 12 个月时进行评估。我们使用多变量线性混合效应模型来估计母体 BMI 与婴儿 Z 分数随时间的关系。
在 861 名未感染 HIV 的婴儿(454 名 HIV 暴露;407 名 HIV 未暴露)中,无论 HIV 暴露状态如何,约 20%的婴儿在 12 个月时超重或肥胖。在多变量分析中,随着母体 BMI 类别的增加,婴儿在 6 周至 12 个月期间的 BMIZ 和 WLZ 评分呈正相关,且与 HIV 暴露状态无关。然而,与所有母体 BMI 类别中未暴露于 HIV 的婴儿相比,暴露于 HIV 的婴儿在 12 个月的年龄内,BMIZ 和 WLZ 轨迹略低。在 HIV 暴露状态下,BMIZ 和 WLZ 评分的差异不能通过 ANC 进入时间或 ART 启动前的母体病毒载量来解释,但对于主要或完全母乳喂养的 HIV 暴露婴儿,Z 评分略高。
这些发现表明,母体 BMI 会影响婴儿早期的体重增加,而与婴儿 HIV 暴露状态无关。减少母体 BMI 的干预措施可能有助于解决对未感染 HIV 的儿童肥胖日益增长的担忧。